Want to see AUTL full AI Analyst Report?
AUTL Stock Chart & Stats
$1.45
-$0.07(-4.61%)
At close: 4:00 PM EDT
$1.45
-$0.07(-4.61%)
Day’s Range― - ―
52-Week Range$1.18 - $2.52
Previous CloseN/A
Volume717.00K
Average Volume (3M)1.08M
Market Cap
$561.59M
Enterprise Value$505.47
Total Cash (Recent Filing)$229.43M
Total Debt (Recent Filing)$79.96M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Oct 29, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding266,155,800
10 Day Avg. Volume1,232,467
30 Day Avg. Volume1,075,893
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.97
Price to Sales (P/S)7.01
P/FCF Ratio-1.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.08Price Target Upside457.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.84
Revenue Forecast (FY)$128.99M
Bulls Say, Bears Say
Bulls Say
Sustained Product Revenue Growth & Upgraded GuidanceSignificant and sustained AUCATZYL sales growth and an upgraded FY26 revenue guide demonstrate durable commercial adoption across treatment centers. The guidance lift improves near-term revenue visibility, supports scale economics, and reduces sole reliance on financing over the next 2–6 months.
Material Gross Margin Improvement & Manufacturing ScaleGross margin stepping to 55% and a 65–70% mature margin target reflect meaningful operational leverage. Early production at the Nucleus facility and cost reductions indicate scalable manufacturing economics that can sustainably lower cost of goods and improve cash conversion as volumes grow.
Extended Runway Via Senior Credit FacilityThe senior secured notes facility plus the initial $75M draw, and expected first two tranches (~$100M combined), materially extend funded runway into Q2 2028 when combined with revenue. This provides funded visibility to execute commercialization and planned data catalysts over a multiyear horizon.
Bears Say
Persistent Negative Cash Flow & High BurnLarge negative operating and free cash flows show ongoing heavy cash burn that tracks net losses. Sustained negative FCF forces reliance on external financing or rapid margin/revenue improvement to fund operations, heightening dilution and liquidity risk over the medium term.
Reliance On Milestone‑Contingent FinancingMaterial portions of available financing depend on meeting revenue milestones and timing windows. Access to up to $150M of tranches is conditional, so failure to hit sales thresholds could compress runway, force cost-cutting, or require more dilutive financing, increasing execution risk.
Elevated SG&A And Ongoing Operating LossesCommercialization has raised SG&A while R&D remains high, producing sizable operating losses. This structurally higher cost base tied to launch activities can limit near-term free cash flow and delays company-level profitability unless revenue growth and margin gains continue as projected.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics’s price range in the past 12 months?
Autolus Therapeutics lowest stock price was $1.18 and its highest was $2.52 in the past 12 months.
What is Autolus Therapeutics’s market cap?
Autolus Therapeutics’s market cap is $561.59M.
When is Autolus Therapeutics’s upcoming earnings report date?
Autolus Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 79 days.
How were Autolus Therapeutics’s earnings last quarter?
Autolus Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.194 by $0.044.
Is Autolus Therapeutics overvalued?
According to Wall Street analysts Autolus Therapeutics’s price is currently Undervalued.
Does Autolus Therapeutics pay dividends?
Autolus Therapeutics does not currently pay dividends.
What is Autolus Therapeutics’s EPS estimate?
Autolus Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Autolus Therapeutics have?
Autolus Therapeutics has 266,155,800 shares outstanding.
What happened to Autolus Therapeutics’s price movement after its last earnings report?
Autolus Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.194. Following the earnings report the stock price went down -7.018%.
Which hedge fund is a major shareholder of Autolus Therapeutics?
Currently, no hedge funds are holding shares in AUTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.08 (457.24% Upside)
$8.08 (457.24% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.3%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.38%
Trailing 12-Months
Company Description
Autolus Therapeutics
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
AUTL Company Deck
AUTL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum for AUCATZYL with substantial QoQ and YoY revenue growth, a material gross margin inflection to 55%, expanding treatment center footprint (80+ centers) and multiple near-term clinical data catalysts. Financially, operating and net losses narrowed and the company secured a strategic credit facility that, combined with revenue expectations, extends cash runway into mid-2028. Offsetting risks highlighted include continued quarterly losses, higher SG&A related to commercialization and one-time charges, sustained R&D burn, some seasonality/visibility concerns, and contingent tranches of financing tied to milestones. On balance, the positive commercial execution, margin improvement, and funded runway outweigh the remaining operational and financing risks described on the call.View all AUTL earnings summariesAUTL Stock 12 Month Forecast
Average Price Target
$8.08
▲(457.24% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
―
Insiders
0.36% Mutual Funds
7.04% Other Institutional Investors
91.74% Public Companies and
Individual Investors